Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression

Cancer Genetics and Cytogenetics

Volumn 115, Issue 1, 1999, Pages 65-69

  Lutchman, Mohini ^a   Pack, Svetlana ^b   Kim, Anthony C ^a   Azim, Anser ^a   Emmert Buck, Michael ^b   Van Huffel, Christophe ^c   Zhuang, Zhengping ^b   Chishti, Athar H ^a,d  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROCYTE BAND 4.9 PROTEIN;

ARTICLE; CARCINOGENESIS; CELL STRAIN 3T3; CHROMOSOME 8P; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; SPHEROCYTOSIS; TUMOR SUPPRESSOR GENE;

3T3 CELLS; ANIMALS; BLOOD PROTEINS; CHROMOSOMES, HUMAN, PAIR 8; CYTOPLASM; DNA, ANTISENSE; EPITHELIUM; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICE; MODELS, GENETIC; PHENOTYPE; PHOSPHOPROTEINS; PHYSICAL CHROMOSOME MAPPING; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033229916     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(99)00081-3     Document Type: Article

References (22)

1. Siegel D., Branton D. Partial purification and characterization of an actin-bundling protein, band 4.9, from human erythrocytes. J Cell Biol. 100:1985;775-785.
2. Rana A.P., Ruff P., Maalouf G.J., Speicher D.W., Chishti A.H. Cloning of human erythroid dematin reveals another member of the villin family. Proc Natl Acad Sci USA. 90:1993;6651-6655.
3. Chishti A.H., Levin A., Branton D. Abolition of actin-bundling by phosphorylation of human erythrocyte protein 4.9. Nature. 334:1988;718-721.
4. Fath K.R., Burgess D.R. Microvillus assembly. Not actin alone. Curr Biol. 56:1995;591-593.
5. Azim A.C., Knoll J.H.M., Beggs A.H., Chishti A.H. Isoform cloning, actin binding, and chromosomal localization of human erythroid dematin, a member of the villin superfamily. J Biol Chem. 270:1995;17407-17413.
6. Lux S.E., Tse W.T., Menninger J.C., John K.M., Harris P., Shalev O., Chilcote R.R., Marchesi S.L., Watkins P.C., Bennett V., McIntosh S., Collins F.S., Francke U., Ward D.C., Forget B.G. Hereditary spherocytosis associated with deletion of human erythrocyte ankyrin gene on chromosome 8. Nature. 345:1990;736-739.
7. Vocke C.D., Pozatti R.O., Bostwick D.G., Florence C.D., Jennings S.B., Strup S.E., Duray P.H., Liotta L.A., Emmert-Buck M.R., Linehan W.M. Analysis of 99 micro-dissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12. Cancer Res. 55:1996;2411-2416.
8. Huang S.F., Xiao S., Renshaw A.A., Loughlin K.R., Hudson T.J., Fletcher J.A. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathol. 149:1996;1565-1573.
9. Cooney K.A., Wetzel J.C., Consolino C.M., Wojno K.J. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res. 56:1996;4150-4153.
10. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15:1997;356-362.
11. Vlietstra R.J., van Alewijk D.C., Hermans K.G., van Streenbrugge G.J., Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58:1998;2720-2723.
12. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 275:1997;1943-1947.
13. Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., Eng C., Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16:1997;64-67.
14. Kim A.C., Peters L.L., Knoll J.H.M., van Huffel C., Ciciotte S.L., Kleyn P.W., Chishti A.H. Limatin (LIMAB1), an actin-binding LIM protein, maps to mouse chromosome 19 and human chromosome 10q25, a region frequently deleted in human cancers. Genomics. 46:1997;291-293.
15. Maier D., Zhang Z., Taylor E., Hamou M.F., Gratzl O., van Meir E.G., Scott R.J., Merlo A. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 as the primary target in low-grade and high grade gliomas. Oncogene. 16:1998;3331-3335.
16. Somerville R.P., Shoshan Y., Eng C., Barnett G., Miller D., Cowell J.K. Molecular analysis of two putative tumor suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene. 17:1998;1755-1757.
17. Pinkel D., Landegent J., Collins C., Fuscoe J., Segraves R., Lucas J., Gray J. Fluorescence in situ hybridization with human chromosome-specific libraries. detection of trisomy 21 and translocations of chromosome 4 Proc Natl Acad Sci USA. 85:1988;9138-9142.
18. Sambrook J, Fritsch EF, Maniatis T (1989): Molecular Cloning, Vol. 1. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 1.38-1.42.
19. Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 23:1993;123-124.
20. Ewing C.M., Ru N., Morton R.A., Robinson J.C., Wheelock M.J., Johnson K.R., Barrett J.C., Isaacs W.B. Chromosome 5 suppresses tumorigenicity of PC-3 prostate cancer cells. correlation with expression of α-catenin and restoration of E-cadherin function Cancer Res. 55:1995;4813-4817.
21. Ben-Ze'ev A. Cytoskeletal and adhesion proteins as tumor suppressors. Curr Opin Cell Biol. 9:1997;99-108.
22. Voeller H.H., Augustus M., Madike V., Bova G.S., Carter K.C., Gelmann E.P. Coding region of NKX3.1, a prostate specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57:1997;4455-4459.